cobas® liat system

Fast, reliable syndromic testing for informed therapeutic decisions

When patients need a fast diagnosis and treatment decision, they count on you to have the right answers, at the right time, wherever you need them. With the cobas® liat system, you can bring gold-standard PCR technology1 directly to any Point of Care setting. From the emergency room to clinics, it enables quick detection of SARS-CoV-2, influenza A/B, respiratory syncytial virus (RSV), strep A, Clostridioides difficile (C. diff), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), and more to come.
The cobas® liat system is compact, user-friendly, and fast—delivering accurate results5 by the time your patient’s appointment ends. It automates complex PCR processes, providing quick, single-sample analysis without support from a skilled technician. With no operator interpretation required, you can confidently rely on results delivered in 20 minutes or less.2-9
Enhance your control of near-patient testing by integrating cobas® liat system with navify® POC digital solutions. You can now streamline your workflow with centralized device and data management while enabling informed decisions right at the Point of Care that help improve clinician outcomes and reduce disease transmission.
Strategically integrated control
The cobas® liat system delivers PCR results in under 20 minutes, streamlining patient care and infection control measures. Learn how it enables rapid diagnostics for efficient triage, remote instrument management to save time, and secure data integration with electronic health or medical records systems.
Banner Health Medical Center: Bringing PCR testing closer to patients
Hear from the Banner Health team as they reveal the real-world impact of gold-standard PCR technology at the Point of Care. Discover how the cobas® liat system empowers healthcare providers to deliver the right test, for the right patient, at the right time, transforming their daily workflow. Watch the video to see how you can elevate patient care with the cobas® liat system in action!
Related products

Targeting high-priority, curable STIs with definitive diagnosis at the Point of Care
Take control of your patients' sexual health by delivering quick, confident results where they're needed most. With the cobas® liat system, you can bring lab-quality PCR testing to the Point of Care, now including the cobas® liat CT/NG and cobas® liat CT/NG/MG assays for sexual health diagnostics.
*Turnaround times vary by assay
Emergency Use Authorization. The cobas® liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), not for any other viruses or pathogens; and
The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
References:
- Hansen GT et al. Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group. J Clin Virol. 2018;102:42-49.
- F. Hoffmann-La Roche Ltd. cobas® liat system, Software version 3.5, User Guide, Publication version
- F. Hoffmann-La Roche Ltd. cobas® Influenza A/B & RSV Test v5, 2020 (CE-IVD) and v1, 2021 (US-IVD), cobas® SARS-CoV-2 & Influenza A/B Test v2, 2020 (CE-IVD) and v2, 2020 (US-IVD)
- F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 Test v1, 2021 (CE-IVD) and v2, 2022 (US-IVD),cobas® Strep A Test v4, 2020 (CE-IVD) and v2, 2017 (US-IVD), cobas® Cdiff Test v4, 2022 (CE-IVD) and v2, 2021 US-IVD)
- F. Hoffmann-La Roche Ltd. cobas® liat system, v11, 2022
- F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test, Package Insert V01, 2020
- F. Hoffmann-La Roche Ltd. cobas® Influenza A/B & RSV package insert, 2021
- F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® liat system, Package Insert V03, 2023
- F. Hoffmann-La Roche Ltd. cobas® Strep A package insert V4, 2020